|
Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System Clinical research trials and Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System. Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System clinical trial. Subjects typically recieve the finest healthcare available for their Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System  Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
For Condition: Neurodegenerative Disease,Parkinson's Disease
Status: Completed
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease. Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.
Details: The ability of the putative excitatory amino acid receptor antagonist, dextromethorphan, to modify psychomotor function safely in patients with neurodegenerative disease will be evaluated using a modified double-blind placebo-controlled design. Therapeutic activity will be rated at various doses by means of standard motor and cognitive performance scales. Safety will be assessed at frequent intervals by clinical observation and laboratory tests.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Parkinson's disease or other neurodegenerative disorders in which excessive stimulation of central glutamatergic pathways is hypothesized. Patients must be in good general health and have no history or clinical evidence of significant cardiac (including dysrhythmias), pulmonary, gastrointestinal, renal, hepatic, endocrine, hematological or psychiatric disease. Patient must not evidence any disorder which in the opinion of the investigator imposes an unnecessary risk to the patient or compromises the scientific interpretation of the data. Individuals of child bearing potential must practice appropriate methods of birth control.
Total Enrollment: 42
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 930183; 93-N-0183
Study Start Date: July 26, 1993
Record last reviewed: July 12, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001365
Other Neurodegenerative Disease Studies:
1. Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) Trial
2. Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
3. Catechol Thioethers in Parkinson's Disease
4. Riluzole to Treat Parkinson's Disease
5. Parkinson's Diseases Susceptibility Genes and Pesticides
Related Studies:
Other Neurodegenerative Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Dextroethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
|
|
|
|
|
|
|
|
